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Purinergic P2X7 receptor (P2X7R), an ATP-gated cation channel, is unique among all other family members because
of its ability to respond to various stimuli and to modulate pro-inflammatory signaling. The activation of P2X7R in
immune cells is absolutely required for mature interleukin -1beta (IL-1beta) and IL-18 production and release. Lung
alveoli are lined by the structural alveolar epithelial type I (AEC I) and alveolar epithelial type II cells (AEC II). AEC I
plays important roles in alveolar barrier protection and fluid homeostasis whereas AEC II synthesizes and secrete
surfactant and prevents alveoli from collapse. Earlier studies indicated that purinergic P2X7 receptors were
specifically expressed in AEC I. However, their implication in alveolar functions has not been explored. This paper
reviews two important signaling pathways of P2X7 receptors in surfactant homeostatsis and Acute Lung Injury (ALI).
Thus, P2X7R resides at the critical nexus of alveolar pathophysiology.Review
Over the last two decades, a total of 19 different pu-
rinergic receptor subtypes (including 7 P2X receptors, 8
P2Y receptors, and 4 adenosine receptors) that can
recognize extracellular ATP and adenosine have been
cloned and characterized [1]. In addition, several families
of ectonucleotidases that hydrolyse ATP to ADP, AMP
and adenosine have been found [2]. These distinct sets of
purinergic receptors and ectonucleotidases are expressed
on the cell surface of the different mammalian cells and
regulate cellular activities through cell-type specific pu-
rinergic signaling systems [3,4].
Controlled ATP release from intact cells was first identi-
fied in neurons [5]. ATP is also released from non-neuronal
cells through vesicular transport [6]. Additional mecha-
nisms for ATP release has been reported including release
through stretch-activated channels, voltage-dependent and
multi-channel anion transporter or permeases [7], cystic fi-
brosis transmembrane conductance regulator (CFTR) [8],
and P2X7 receptor associated connexin and pannexin he-
michannels [9]. ATP release from mouse neutrophil occurs
through connexin-43 hemi channels [10].
Extracellular ATP has two fates before being degraded
by the ectonucleotidases. The released ATP either acts onCorrespondence: amarjitmisra@gmail.com
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reproduction in any medium, provided the orthe purinoceptors of the same cell (autocrine) or the
neighboring cells (paracrine). Autocrine signaling through
the purinergic receptors regulates the neutrophil chemo-
taxis via ATP release from polarized neutrophil in re-
sponse to chemotactic mediators [11]. The activated
T cells also induce the release of ATP through pannexin 1
channels. These hemichannels translocate with P2X re-
ceptors to the immune synapse, where they promote Ca2+
influx and cell activation through autocrine purinergic sig-
naling [12,13]. The activation of purinergic receptors in
immune cells can elicit either positive or negative feedback
mechanisms and thus tightly regulate immune responses.
Paracrine purinergic signaling regulates a wide range of
physiological process, including immune cell functions
[14,15]. ATP released from damaged or stressed host cells
serves as an important function in the recognition of ‘dan-
ger signals’ and guides phagocytes to inflammatory sites.
Thus promotes clearance of damaged and apoptotic cells
[16]. In response to damage-associated molecular patterns
(DAMPs) and pathogen-associated molecular patterns
(PAMPs), activation of inflammasome and the subsequent
release of interleukin-1β (IL-1β) require purinergic sing-
nalling. In the cytoplasm nucleotides are concentrated in
the micomolar or even millimolar level, while the extracel-
lular concentration is extremely low, usually in the
nanomolar range [17]. ATP is rapidly released upon dam-
age of plasma membrane and diffuses throughout the
pericellular space and bind to specific receptors expressedhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Mishra Journal of Biomedical Science 2013, 20:26 Page 2 of 6
http://www.jbiomedsci.com/content/20/1/26by virtually all immune cells [18]. Diffusion of nucleotides
is drastically controlled via degradation by ecto-nucleotidases
expressed on the plasma membranes of most cells. Rapid
metabolism of extracellular ATP generates the anti-
inflammatory metabolite adenosine and terminates the
alert-signal to a checkpoint [19].
P2X7 receptor and inflammation
P2X7 receptors are expressed primarily on the cells of
hematopoietic lineage. The distribution of P2X7 receptor
has been studied by permeability and RT-PCR analysis in
cultured monocytes/macrophages [20], phagocytes [21],
dendritic cells [22], T lymphocytes [23], B lymphocytes
[24], mast cells [25] and eosinophils [26]. P2X7 receptor
has also been identified in fibroblasts, endothelial cells and
epithelial cells [27,28]. Our laboratory has reported previ-
ously specific expression of P2X7 receptors in alveolar
type I epithelial cells (AEC I) [29].
IL-1β and IL-18 are pro-inflammatory cytokines that re-
quires processing by interleukin converting enzyme (ICE,
also known as caspase-1) at specific aspartic residues for
mature molecule production. Activation of P2X7 receptor
on human macrophages triggers the release of these two
cytokines [30-32]. P2X7 receptor is also required for
inflammasome assembly and caspase activation [33]. Stud-
ies on P2X7 receptor knock-out mice have shown that ab-
sence of P2X7 receptor leads to an inability to release
IL-1β in response to ATP stimulation from peritoneal
macrophages [34]. P2X7 null mice therefore have impaired
cytokine signaling cascade in vivo. This suggests that P2X7
receptor activation provides signals for maturation and re-
lease of IL-1β and initiation of a cytokine cascade.
The unprocessed and mature form of IL-1β was found
in the shed microvesicles [35]. P2X7–mediated micro-
vesicle formation and shedding might be a crucial pathway
for secretory protein release from cytoplasm. L-selectin
(CD62L; a C-type lectin) and CD23 (low affinity IgE
receptor) are involved in the adhesive interaction and
rolling behavior of lymphocytes on endothelial cells [36].
P2X7 receptor contributes to the regulation of intercellu-
lar interactions and to the generation of soluble markers.-
Elevated levels of CD62L and CD23 in sera have
been reported from B-cell chronic lymphocytic leukaemia
(B-CLL) patients [37]. ATP-induced L-selectins and CD23
shedding have also been shown to decrease in P2X7 re-
ceptor knock-out mice, indicating the pathophysiological
role of P2X7 receptor [38]. Involvement of P2X7 receptor
in ATP-induced apoptosis is well documented in lympho-
cytes, monocytes, macrophages, murine thymocytes, and
dendritic cells [39,40]. P2X7 receptor activation has been
shown to stimulate the activity of intracellular caspases
prior to ATP-induced apoptosis. K+ efflux through the
P2X7 receptor ion channel leads to cell shrinkage and ac-
tivation of caspase cascades [41].P2X7 receptor and regulation of lung surfactant secretion
Lung surfactant is a lipid-enriched substance comprising
of 80% glycerophospholipids, 10% cholestrol and about
5-10% proteins. Di-palmitoylphosphatidyl choline (DPPC)
is the major glycerophospholipid present in surfactant.
The major function of surfactant is to reduce surface ten-
sion in the lung. There are 4 major surfactant proteins.
SP-B and SP-C are synthesized in endoplasmic reticulumn
and further processed by Golgi apparatus. These proteins
are stored in lamellar bodies preceeding exocytosis [42].
However, SP-A and SP-D secretes constitutively independ-
ent of lamellar bodies [43]. Alveolar epithelial type II cells
(AEC II) stores and secrete surfactant. Physiologically,
mechanical stretch, labor, and ventilation induce surfactant
secretion from AEC II. However, recent experiments sug-
gests that lung distensions rather than systemic changes ac-
companying hyperventilation (Pco2, Po2, and pH) increases
surfactant secretion [44]. The mechanical stretch of the
AEC II during an enhanced inspiration (‘sigh’) is a direct
stimulus for surfactant secretion.
The commonly held view of regulated surfactant se-
cretion from AEC II involves cell membrane receptors
including β2-adrenergic, adenosine A2B, and purinergic
P2Y2. ATP, UTP, adenosine, platelet activating factor, LPS,
and IL-1β are the known agonists to stimulate surfactant
secretion [45]. Stimulation of these receptors ultimately
leads to activation of protein kinase A (PKA), protein kin-
ase C (PKC) and calcium and calmodulin kinase (CaMK)
and their downstream partners. The purinergic metabo-
tropic receptor, P2Y2, is coupled to the G protein Gq,
which stimulates phospholipase C (PLC) and hydrolyzes
phosphotidylinositol biphosphate into diacylglycerol (DAG)
and inositol triphosphate (IP3) [46]. The increase in intra-
cellular Ca2+ concentration results in enhanced surfactant
secretion [47,48]. Surfactant exocytosis in AEC II is ex-
tremely sensitive to perturbations of Ca2+. In vitro, secreta-
gogues including β2-adrenergic agonists (terbutaline), A2B
receptor agonists (adenosine), P2Y2 receptor agonists (ATP
and UTP), PKC activators (phorbol esters) and calcium ion-
ophores (A23187) have been shown to stimulate surfactant
exocytosis. Terbutaline and adenosine activate adenyl cy-
clase which further stimulates PKA-mediated signaling.
Moreover, ATP and phorbol esters activate PKC and down-
stream signaling molecules. The ionophores increase the
intracellular calcium concentrations which further activates
PKC and CAMK II. Activation of various kinases leads to
phosphorylation of various proteins resulting in surfactant
exocytosis. However, the mechanism of how the phosphor-
ylation induces secretion is incompletely understood.
Contribution of AEC I and P2X7 receptor signaling in
surfactant secretion
The alveolar epithelium has two specialized epithelial cell
types: the terminally differentiated squamous AEC I and
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cover 95% of the alveolar surface and form a tight epithe-
lial barrier with the AEC II to facilitate gas and water ex-
change. Alveolar epithelial cells are closely associated with
endothelial cells, stromal fibroblasts, inflammatory cells,
and the accompanying extracellular matrix. The function
of AEC I has been relatively unexplored because it has
been extremely difficult to isolate and culture viable AEC I
[49]. Our lab and other labs have developed methods to
isolate AEC I [50].
AEC I respond to the forces generated by mechanical
ventilation i.e. conversion of physical forces on the cell
membranes and/or receptors into activation of intracellular
signaling pathway leading to Ca2+ wave generation. The
intracellular Ca2+ contributes to integrate signaling in lung
epithelium. The mechanisms underlying the coordination
of intracellular Ca2+ changes in AEC I to neighboring AEC
II involve diffusion of ions/second messenger molecules
through gap junctions and release of ATP or UTP in the
extracellular spaces. This subsequently activates Ca2+ sig-
naling pathways in AEC II through purinergic receptors
and induces surfactant release. Recent studies using the
in situ technique confirm that calcium waves passed from
AEC I to AEC II result in the release of surfactant from
AEC II [51]. Mechanical stimulation of AEC I-like cells in
heterocellular culture propagated calcium to neighboring
AEC II-like cells mainly via an apyrase-sensitive mechan-
ism, suggesting that ATP is an extracellular mediator of al-
veolar cell communications [52]. ATP is produced by AEC
I in response to mechanical stimulation and in turn trig-
gers surfactant secretion from AEC II [53]. However, the
mechanism of ATP release from AEC I has not been
established.
P2X7 receptors are specifically expressed in AEC I [29].
The expression of P2X7 receptor couples caveolin-1 as
Cav-1 knock-out mice shows reduced P2X7 receptor im-
munoreactivity in lung [54]. Previously, we have shown
that the stimulation of P2X7 receptor in AEC I releases
soluble mediator, ATP, which acts in a paracrine fashion on
AEC II. Activation of P2Y2 receptors by extracellular ATP
increases surfactant secretion from AEC II via a PKC–
dependent signaling pathway. Moreover, the paracrine
regulation of surfactant exocytosis by P2X7 receptor is a
physiologically relevant phenomenon as the P2X7 receptor
knock-out mice are less responsive to hyperventilation-
induced surfactant release [55]. Therefore, P2X7 receptors
in AEC I are an important regulator of surfactant secretion
and AEC I and AEC II communications.
Acute lung injury
Acute Respiratory Disease Syndrome (ARDS) is acute lung
injury (ALI) of the alveolar/capillary membrane. ARDS is
characterized by permeability pulmonary edema (fluid in
the alveolar space) and acute respiratory failure. It is definedas acute respiratory distress with diffuse alveolar infiltrates
on chest X-ray, severe hypoxemia (PaO2/FIO2 <200). The
etiology of ARDS includes aspiration of gastric contents,
pneumonia, smoke inhalation, sepsis, trauma, and drug
overdose, multiple transfusions, pancreatitis, and venous air
embolism. Sepsis is an important predisposing factor,
present in 40% of ARDS patients. Multiple risk factors in-
crease the chance of developing ARDS. ALI is a common
complication of mechanical ventilated patients and often
synergized the upshots with sepsis background. Mechanical
ventilation augments the acute lung injury caused by bac-
terial products.
Alveolar cells produce a range of proinflammatory cyto-
kines when exposed to bacterial products. Importantly,
ATP is a potent candidate to activate the innate immune
response. There is a significant degree of purinergic inter-
play in the prognosis of the ALI pathogenecity. The patho-
genesis of the disease can be inferred by concentering on
the factors that are responsible for the accumulation of
protein-rich and neutrophillic pulmonary edema in the
lung and, the mechanisms that impair the removal of pul-
monary edema fluid [56]. Inflammatory cells from the
lung are the inciting factors in the pathogenesis of ALI.
The protein –rich edema fluid in ALI is associated with
large numbers of neutrophils, denuded alveolar epithelial
cells and proinflammatory markers including cytokines,
oxidants procoagulant factors and proteases [57] .
The initial cause of ALI is the lung vascular injury. An
increase in lung vascular permeability occurs primarily at
the level of lung microcirculation, which in turn results in
the accumulation of protein-rich pulmonary edema fluid,
even in the presence of normal lung vascular pressur [58].
A sustained loss of normal endothelial barrier function is
best described in neutrophil-dependent lung injury [59].
Neutrophil sequestration and activation in the lung micro-
vasculature leads to degranulation and release of several
toxic mediators, including ROS, proinflammatory cyto-
kines and procoagulant molecules, resulting in increase of
vascular permeability.
Alveolar epithelial injury is another cardinal characteristic
of ALI. Although the mechanisms responsible for epithelial
injury in ALI are poorly understood, it appears that neutro-
phil and their products are primarily responsible for the in-
creased paracellular alveolar permeability in ALI. However,
neutrophil can cross the alveolar epithelium without affect-
ing the lung epithelial permeability [57,60]. In pathological
states the migration of a large number of neutrophils re-
sults in increased epithelial injury [56]. Furthermore, the
degree of neutrophil activation (priming) by exposure to
chemokines and other proinflammatory cytokines seems to
play a crucial role in the alveolar epithelial injury as neutro-
phils crawl into the distal airspaces. Transepithelial migra-
tion of neutrophils into the distal airspaces involves three
distinct and sequential steps of adhesion, migration and
Figure 1 Proposed pathophysiological role of P2X7 receptor signaling in the normal and injured alveolus.
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thelial surface by β2-integrins [61,62]. The initial adhesion
of neutrophils to the basolateral surface is primarily medi-
ated by CD11b/CD18 molecules [63]. However, CD18-
independent transmigration of neutrophils has also been
documented. The paracellular route of neutrophil migra-
tion to the distal airspaces is also associated with CD47, a
cell-surface molecule expressed on epithelial cells and neu-
trophils [64]. Once they traverse the epithelium and enter
the airspaces, neutrophils adhere to the apical surface,
where they phagocytize and kill bacteria. The release of
toxic intracellular molecules from activated neutrophils in-
duces dissolution of tight junction and necrosis of AEC I.
Finally, apoptosis and phagocytosis of inflammatory cells
are critical for the resolution of inflammation and mitiga-
tion of lung tissue damage.
P2X7 receptor signaling in acute lung injury
P2X7 receptor knock-out mice are less susceptible to
smoke-induced lung inflammation and emphysema. P2X7
receptor expressions increased rapidly in alveolar macro-
phages, circulating neutrophils and in whole lung tissue
following smoke-induced lung inflammation and are
blocked by selective intra-pulmonary P2X7 receptor inhib-
ition [65]. Furthermore, P2X7 receptor knock-out mice
shows reduced inflammation and lung fibrosis to airway-administered bleomycin. In the presence of ATPγS, a stable
P2X7 receptor agonist, lung cell recruitment and matrix
remodeling proteins such as matrixmetalloproteinase-9
(MMP-9) and tissue-inhibitor of metalloproteinase
(TIMP-1) were increased rapidly. Therefore, P2X7 recep-
tor plays an important pro-inflammatory function in in-
jured alveolus. Delving into the mechanism mediated by
P2X7 receptor in injury, we found that P2X7 receptors are
involved in soluble Vascular Cell Adhesion Molecule-1
(sVCAM-1) release from AEC I (Unpublished data).
sVCAM-1 resembles an important regulatory component
of the inflammatory response and is detectable in serum
and other body fluids. sVCAM-1 level is elevated in alveolar
lining fluid from pneumonia and asthma patients [66,67].
Moreover, our data suggest the metalloprotease, ADAM17
are responsible for VCAM-1 shedding from AEC I surface
in a P2X7 receptor-dependent manner. This P2X7 receptor
mediated shedding of VCAM-1 from AEC I is crucial for
the recruitment of neutrophils in the alveolar space.
Conclusions
P2X7 receptor plays important roles in immunity, inflam-
mation, bone homeostasis, neurological function and neo-
plasia. There is increase body of evidence implicating P2X7
receptor in various pathological conditions of pulmonary,
cardiac, renal, skeletal muscle and central nervous system
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of these disorders.
The involvement of P2X7 receptor in the pathogenesis of
pulmonary emphysema [68], and COPD [69] has been well
documented. Pulmonary fibrosis is characterized by inflam-
mation and fibrosis of the interstitium and destruction of
alveolar histoarchitecture. Recent animal studies have iden-
tified the importance of P2X7 receptor and pannexin-1
complex in IL-1β maturation, inflammation and evolution
to pulmonary fibrosis [70].
AEC I play important roles in alveolar barrier protection
and fluid homeostasis. Earlier studies indicated that
purinergic P2X7 receptors were specifically expressed in
AEC I. Although P2X7 receptor-mediated critical signaling
pathways in immune cells have been identified, less is
known about their functions in alveolar pathophysiology.
Several line of evidence suggests that the pro-inflammatory
P2X7 receptor signaling are druggable targets in lung in-
flammatory diseases. However, the mechanism of P2X7
receptor-mediated signaling pathways in alveolus in par-
ticular AEC I are not well understood.
Finally, we propose the following models for P2X7 recep-
tor signaling in alveolus (Figure 1). (A) In the normal alveo-
lus, activation of P2X7 receptor in AEC I cell surface leads
to ATP release. ATP in the extracellular space activates
neighboring AEC II and stimulates surfactant secretion
through P2Y2 receptor signaling pathway. (B) In the in-
jured lung, there is sloughing of both bronchial and alveo-
lar epithelial cells, denuded alveolar basement membrane.
Alveolar macrophages secrete cytokines; IL-1β, IL-6,
and TNF-α, that act locally on AEC I. This increases the
VCAM-1 expression in AEC I membrane. P2X7 receptor
stimulation on AEC I modulate ADAM17 activity through
MAPK activation. ADAM17 shed VCAM-1 from the
AEC I surface. sVCAM-1 in the alveolar space stimulate
neutrophil chemotaxis and sequestrations. Thus, P2X7R
resides at the critical nexus of surfactant regulation, cyto-
kine modulation, neutrophil recruitment and inflammation
in lung.
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